NASDAQ: CELCCelcuity Inc Stock
$16.94-0.30 (-1.74%)
Updated Apr 24, 2024
CELC Price
$16.94
Fair Value Price
-$0.29
Market Cap
$515.88M
52 Week Low
$8.39
52 Week High
$22.19
P/E
-6.3x
P/B
3.69x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$63.78M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.37
Operating Cash Flow
-$54M
Beta
0.82
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CELC Overview
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CELC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CELC ($16.94) is overvalued by 6,013.32% relative to our estimate of its Fair Value price of -$0.29 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CELC ($16.94) is not significantly undervalued (6,013.32%) relative to our estimate of its Fair Value price of -$0.29 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CELC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CELC due diligence checks available for Premium users.
Be the first to know about important CELC news, forecast changes, insider trades & much more!
CELC News
Valuation
CELC fair value
Fair Value of CELC stock based on Discounted Cash Flow (DCF)
Price
$16.94
Fair Value
-$0.29
Undervalued by
6,013.32%
CELC ($16.94) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CELC ($16.94) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CELC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CELC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.3x
Industry
15.69x
Market
41.27x
CELC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.69x
Industry
5.86x
CELC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CELC's financial health
Profit margin
Revenue
$0.0
Net Income
-$18.8M
Profit Margin
0%
CELC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$191.2M
Liabilities
$51.5M
Debt to equity
0.37
CELC's short-term assets ($190.59M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CELC's short-term assets ($190.59M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CELC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CELC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$18.5M
Investing
-$41.2M
Financing
$64.7M
CELC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CELC vs Biotech Stocks
Celcuity Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.